Healthcare company Healius anticipates recording FY24 underlying EBITDA of $345-350 million and underlying EBIT of $60-65 million.
Pathology volumes increased by 3.9% from January to May, offset by lower GP market fees amid inflationary pressures.
The company expects to exceed its FY24 pathology transformation savings target of $15 million.